EUVIMEDEUVIMED entdecken
VergleichsstudieRandomisierte kontrollierte Studie

Pharmacokinetics and Bioequivalence of 2 Nifedipine Controlled‐Release Tablets: A Randomized, Single‐Dose, 2‐Period Crossover Study in Healthy Chinese Volunteers Under Fasting and Fed Conditions

Liang Xin, Qing Chen, Dandan Chen, Yijhen Li, Yiqun Li, Qingqing Wu, Yang Zou, Wei Wang, Jingying Jia, Chen Yu, Yanmei Liu

Clinical Pharmacology in Drug Development · 2023

DOI: 10.1002/cpdd.1258 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Pharmacology in Drug Development, 2023. Verfasst von Liang Xin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Xuhui Central Hospital/Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: East Asian People, Nifedipine. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim of this study was to evaluate the bioequivalence of generic nifedipine controlled‐release tablet compared to branded product under fasting and fed conditions. A randomized, single‐dose, 2‐period, crossover study with a 7‐day washout period was performed in 84 healthy Chinese volunteers (fasting cohort, n = 42; fed cohort, n = 42). In each study period, volunteers were assigned to receive a single oral dose of the generic or reference product (30 mg). Blood samples were collected before dosing and up to 72 hours after administration. The plasma concentration of nifedipine was determined by a validated liquid chromatography–tandem mass spectrometry method. Pharmacokinetic parameters were obtained using a noncompartmental model and log‐transformed pharmacokinetic parameters (maximum plasma concentration, area under the plasma concentration–time curve (AUC) from time 0 to the last measurable concentration, AUC from time 0 to infinity) were used to evaluate bioequivalence. The results showed that the 90% confidence interval for the geometric mean ratio of pharmacokinetic parameters of the test and reference products ranged from 80.0% to 125.0% in both the fasting and fed cohorts, meeting the criteria for bioequivalence. No serious adverse events were reported throughout the study and no adverse events led to withdrawal from the study. Food effects were found in both the test and reference products, with mean maximum plasma concentration, AUC from time 0 to the last measurable concentration, and AUC from time 0 to infinity increased by 23.7%, 20.7%, and 20.5%, respectively, for the test product and 35.2%, 13.4%, and 14.7% for the reference product after a high‐fat and high‐calorie breakfast.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

East Asian PeopleNifedipineHumansArea Under CurveCross-Over StudiesDelayed-Action PreparationsFastingTabletsTherapeutic EquivalencyHealthy Volunteers

Stichwörter der Autor:innen

LC-MS/MSbioequivalencecontrolled-release formulationnifedipinepharmacokinetics

Substanzen

Delayed-Action PreparationsNifedipineTablets

Autor:innen und Institutionen

  • Shanghai Xuhui Central Hospital/Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.
  • Shanghai Engineering Research Center of Phase I Clinical Research & Quality Consistency Evaluation for Drugs, Shanghai, China.
  • Shanghai Institute of Clinical Mass Spectrometry, Shanghai, China.
  • Beijing Honglin Pharma. Co., Ltd., Beijing, China.

Zitieren

APA

Xin, L., Chen, Q., Chen, D., Li, Y., Li, Y., Wu, Q., Zou, Y., Wang, W., Jia, J., Yu, C., & Liu, Y. (2023). Pharmacokinetics and Bioequivalence of 2 Nifedipine Controlled‐Release Tablets: A Randomized, Single‐Dose, 2‐Period Crossover Study in Healthy Chinese Volunteers Under Fasting and Fed Conditions. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1258

Vancouver

Xin L, Chen Q, Chen D, Li Y, Li Y, Wu Q, et al. Pharmacokinetics and Bioequivalence of 2 Nifedipine Controlled‐Release Tablets: A Randomized, Single‐Dose, 2‐Period Crossover Study in Healthy Chinese Volunteers Under Fasting and Fed Conditions. Clinical Pharmacology in Drug Development. 2023. doi:10.1002/cpdd.1258

BibTeX
@article{Xin2023,
  author = {Xin, Liang and Chen, Qing and Chen, Dandan and Li, Yijhen and Li, Yiqun and Wu, Qingqing and Zou, Yang and Wang, Wei and Jia, Jingying and Yu, Chen and Liu, Yanmei},
  title = {Pharmacokinetics and Bioequivalence of 2 Nifedipine Controlled‐Release Tablets: A Randomized, Single‐Dose, 2‐Period Crossover Study in Healthy Chinese Volunteers Under Fasting and Fed Conditions},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2023},
  doi = {10.1002/cpdd.1258}
}
Kostenlos starten →